Upregulation of S100A6 in patients with endometriosis and its role in ectopic endometrial stromal cells

Peng, Yaoming; Lin, Jiabin; Ma, Junyan; Lin, Kejian; Xu, Kang

doi:10.1080/09513590.2018.1451506

Cited by 6 publications

(4 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Significantly higher levels of mRNA and protein of S100A6 are also characteristic for endometriosis, a benign growth of endometrial tissue outside the uterus. S100A6 expression is enhanced in ectopic endometrial tissues compared to eutopic ones [ 184 ]. S100A6 knockdown in ectopic endometrial stromal cells (ESCs) suppressed p38/MAPK activity and inhibited cell viability, migration and invasion, suggesting that S100A6 may contribute to the pathogenesis of endometriosis.…”

Section: S100a6 In Various Pathologiesmentioning

confidence: 99%

S100A6 Protein—Expression and Function in Norm and Pathology

Leśniak

Filipek

2023

IJMS

View full text Add to dashboard Cite

S100A6, also known as calcyclin, is a calcium-binding protein belonging to the S100 protein family. It was first identified and purified more than 30 years ago. Initial structural studies, focused mostly on the mode and affinity of Ca2+ binding and resolution of the resultant conformational changes, were soon complemented by research on its expression, localization and identification of binding partners. With time, the use of biophysical methods helped to resolve the structure and versatility of S100A6 complexes with some of its ligands. Meanwhile, it became clear that S100A6 expression was altered in various pathological states and correlated with the stage/progression of many diseases, including cancers, indicative of its important, and possibly causative, role in some of these diseases. This, in turn, prompted researchers to look for the mechanism of S100A6 action and to identify the intermediary signaling pathways and effectors. After all these years, our knowledge on various aspects of S100A6 biology is robust but still incomplete. The list of S100A6 ligands is growing all the time, as is our understanding of the physiological importance of these interactions. The present review summarizes available data concerning S100A6 expression/localization, interaction with intracellular and extracellular targets, involvement in Ca2+-dependent cellular processes and association with various pathologies.

show abstract

Section: S100a6 In Various Pathologiesmentioning

confidence: 99%

S100A6 Protein—Expression and Function in Norm and Pathology

Leśniak

Filipek

2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Retrograde menstruation is considered to be the primary etiology, followed by the processes of attachment, invasion, proliferation and maintenance . Although the underlying pathogenesis of endometriosis is still poorly understood, many cell migration‐related and invasion‐related molecules are associated with the progression of endometriosis …”

Section: Introductionmentioning

confidence: 99%

“…3 Although the underlying pathogenesis of endometriosis is still poorly understood, many cell migration-related and invasion-related molecules are associated with the progression of endometriosis. 4,5 Tensin 1 (TNS1) is a focal adhesion phosphoprotein molecule localized in cytoplasm that plays a role in the transmembrane junctions between the extracellular matrix and cytoskeleton. 6 Cells lacking TNS1 migrate more slowly than their normal counterparts, demonstrating that TNS1 is critical for normal cell migratory processes.…”

Section: Introductionmentioning

confidence: 99%

Gonadotropin‐releasing hormone agonist induces downregulation of tensin 1 in women with endometriosis

Rahmawati

Yang

Lei

et al. 2018

Acta Obstet Gynecol Scand

View full text Add to dashboard Cite

Introduction Many cell migration‐related molecules are associated with endometriosis. Tensin 1 (TNS1), which has been implicated in cell migration, may play a role in endometriosis. The study goal was to evaluate the TNS1 expression in endometrial tissue and serum from women with endometriosis treated with gonadotropin‐releasing hormone agonist (GnRHa). Material and methods Tissue and serum samples were collected from women with endometriosis who were treated (n = 29) with GnRHa or untreated (n = 30). TNS1 mRNA was examined using quantitative PCR. TNS1 protein levels in tissue and serum samples were investigated using Western blot, immunohistochemistry and ELISA. Eleven women with endometriosis participated in a follow‐up investigation of serum TNS1 before and after GnRHa treatment. Results TNS1 mRNA (P = 0.006) and protein (P = 0.001) were significantly downregulated in endometriotic tissue from women with endometriosis who received GnRHa. Immunolocalization of TNS1 showed strong expression in the epithelial and stromal cells of endometriotic tissue from women untreated with GnRHa, whereas endometriotic tissue from GnRHa‐treated women showed low TNS1 expression. Follow‐up monitoring of serum TNS1 concentration in 11 women showed an average decrease in concentration of 53%, from 294.9 ± 66.69 to 140.3 ± 55.21 pg/mL, following GnRHa treatment (P = 0.003). Conclusions GnRHa induces downregulation of TNS1 in tissue and serum in women with endometriosis. These results emphasize the importance TNS1 as a potential therapeutic molecular target for the treatment of endometriosis with GnRHa.

show abstract

“…Inhibition of CacyBP/SIP phosphorylation can also reduce p38MAPK activity in euESCs. This regulation of the S100A6/CacyBP/SIP/p38MAPK axis may be a promising therapeutic target [147]. In euESCs, S100A6 and β-catenin are expressed in a synergistic manner [148,149].…”

Section: S100a6 In Other Diseasesmentioning

confidence: 98%

The Role of S100A6 in Human Diseases: Molecular Mechanisms and Therapeutic Potential

Yang

Zhu

et al. 2023

Biomolecules

View full text Add to dashboard Cite

S100A6, also known as calcyclin, is a low-molecular-weight Ca2+-binding protein from the S100 family that contains two EF-hands. S100A6 is expressed in a variety of mammalian cells and tissues. It is also expressed in lung, colorectal, pancreatic, and liver cancers, as well as other cancers such as melanoma. S100A6 has many molecular functions related to cell proliferation, the cell cycle, cell differentiation, and the cytoskeleton. It is not only involved in tumor invasion, proliferation, and migration, but also the pathogenesis of other non-neoplastic diseases. In this review, we focus on the molecular mechanisms and potential therapeutic targets of S100A6 in tumors, nervous system diseases, leukemia, endometriosis, cardiovascular disease, osteoarthritis, and other related diseases.

show abstract

Upregulation of S100A6 in patients with endometriosis and its role in ectopic endometrial stromal cells

Cited by 6 publications

References 27 publications

S100A6 Protein—Expression and Function in Norm and Pathology

S100A6 Protein—Expression and Function in Norm and Pathology

Gonadotropin‐releasing hormone agonist induces downregulation of tensin 1 in women with endometriosis

The Role of S100A6 in Human Diseases: Molecular Mechanisms and Therapeutic Potential

Contact Info

Product

Resources

About